Core Viewpoint - Genenta Science has entered into a securities purchase agreement to sell 4,285,715 American Depositary Shares (ADSs) at $3.50 per ADS, aiming for gross proceeds of approximately $15.0 million before expenses [1][2]. Group 1: Offering Details - The offering involves the sale of securities solely by Genenta, with no warrants or derivative securities issued [1]. - Maxim Group LLC is the lead placement agent, while Rodman & Renshaw LLC acts as the co-placement agent for the offering [2]. - The expected closing date for the offering is around October 28, 2025, pending customary closing conditions [2]. Group 2: Use of Proceeds - Genenta plans to utilize the net proceeds from the offering for working capital and general corporate purposes [2]. Group 3: Company Overview - Genenta Science is a clinical-stage immuno-oncology company focused on developing proprietary hematopoietic stem cell therapies for solid tumor cancers [5]. - The company's lead product candidate, Temferon™, aims to express immune-therapeutic payloads within the tumor microenvironment, potentially enhancing immune responses [5]. - Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme (GBM) patients and has initiated a Phase 1/2a study for metastatic Renal Cell Carcinoma, which will include combinations with immune checkpoint inhibitors [5].

Company Highlights - Wellgistics Health, Inc. (NASDAQ:WGRX) experienced a significant price increase of 168.16%, reaching $1.08, driven by its blockchain initiative in prescription drug tracking [1][5] - MaxsMaking Inc. (NASDAQ:MAMK) saw its stock price rise by 148.70% to $7.43, following a successful IPO that raised $6.5 million, indicating strong investor interest in its innovative textile production [1][5] - Inhibrx Biosciences, Inc. (NASDAQ:INBX) reported a stock price surge of 94.43% to $55.13, likely due to positive developments in its clinical trials for a rare bone cancer treatment [2][5] - Genenta Science S.p.A. (NASDAQ:GNTA) experienced a 92.72% increase in stock price to $6.22, attributed to promising clinical trial results and a strategic partnership with ANEMOCYTE [3] Market Dynamics - The significant price movements across these companies reflect diverse investor interest in sectors such as healthcare, biotechnology, and consumer goods, influenced by clinical trial outcomes, strategic partnerships, and innovative product offerings [4]

Core Insights - Genenta Science and ANEMOCYTE have announced a strategic collaboration focusing on off-the-shelf lentiviral vector (LVV) Plasmid DNA technology, expanding their existing partnership in plasmid DNA production [1][2][3] - The collaboration aims to enhance ANEMOCYTE's offerings by utilizing Genenta's established LVV Plasmid DNA technology, which is based on foundational research by Professor Luigi Naldini [2][3] - This partnership is expected to support the development of advanced therapy programs across the life sciences industry, ensuring clients have access to reliable and scalable solutions [3] Company Overview - Genenta Science is a clinical-stage immuno-oncology company developing a proprietary hematopoietic stem cell therapy for solid tumor cancers, with its lead product candidate being Temferon™ [5] - Temferon™ is designed to express immune-therapeutic payloads within the tumor microenvironment, potentially enhancing T cell responses and breaking immune tolerance [5] - ANEMOCYTE is a Biotech Manufacturing Organization based in Italy, specializing in the development and manufacturing of pDNA and mRNA, with over 25 years of expertise in innovative therapies [4]

MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced a strategic collaboration with a focus on off-the-shelf lentiviral vector (“LVV”) Plasmid DNA technology platform. This new agreement builds and expands on the existing successful partnership between the two companies, which has focused on the production of Plasmid DNA. The partnership leverages Genen ...

Core Insights - Genenta Science is conducting ongoing clinical trials for its immuno-oncology product, Temferon, focusing on glioblastoma multiforme and genitourinary tumors [1][3][6] Group 1: Glioblastoma Multiforme Study - A total of 38 patients have been enrolled in the glioblastoma multiforme study, with 25 patients receiving Temferon [1] - The two-year survival rate for unmethylated MGMT (uMGMT) patients in the GBM trial is 29%, with a median overall survival of 17 months, compared to historical cohorts showing a 14% survival rate and a median overall survival of 13 to 15 months [2] - Two patients have been enrolled in a long-term follow-up study, with one showing no disease progression and the other stabilizing after initial progression, indicating potential efficacy of Temferon [1] Group 2: Genitourinary Tumor Study - The TEM-GU Phase 1 study has begun recruitment, aiming to enroll 12 patients with genitourinary tumors, administering Temferon at a fixed dose of 4 million genetically modified cells per kilogram [3] - The study will evaluate the safety and tolerability of Temferon in combination with immune checkpoint inhibitors or tyrosine kinase inhibitors [3] Group 3: Mechanism of Action - Temferon works by reprogramming the tumor microenvironment to enhance adaptive immune responses [4] - A scientific manuscript has been accepted for publication, demonstrating Temferon's potential to enhance CAR-T activity in preclinical models [4][5] Group 4: Company Overview - Genenta Science is a clinical-stage immuno-oncology company developing hematopoietic stem cell therapy for solid tumors, with Temferon as its first product candidate [6] - The company has completed a Phase 1 trial for newly diagnosed GBM patients with an unmethylated MGMT gene promoter, suggesting potential for reprogramming the tumor microenvironment [6]

Core Insights - Genenta Science has announced a collaboration with Anemocyte to establish Cell Banks and produce Plasmids for viral vector production, marking a significant milestone in immuno-oncology therapies [1][2] Company Overview - Genenta Science is a clinical-stage immuno-oncology company focused on developing hematopoietic stem cell therapy for solid tumor cancers, with its lead product candidate being Temferon™ [5] - Anemocyte is a Biotech Manufacturing Organization based in Italy, specializing in the development and production of pDNA and mRNA, with over 25 years of experience in manufacturing innovative therapies [4] Collaboration Details - The partnership aims to leverage Genenta's innovative platform and Anemocyte's expertise in producing high-quality starting materials, which is crucial for advancing clinical trials [2][3] - Anemocyte's team has played a vital role in the manufacturing process, confirming the quality and reliability of their plasmid DNA for therapeutic products [3] Clinical Development - Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme patients and has initiated a Phase 1/2a study for metastatic Renal Cell Carcinoma, which will include combinations with immune checkpoint inhibitors [5]

Core Insights - Genenta Science, a leader in immuno-oncology and cell-based therapeutics, is advancing its pipeline with a strategic financing of €20 million ($22.7 million) through a Mandatory Convertible Bond to ENEA Tech and Biomedical [2] - The company is focused on the development of Temferon™ for metastatic Renal Cell Cancer (mRCC) and has raised an additional €3.0 million ($3.2 million) via an at-the-market facility [2] - CEO Pierluigi Paracchi will present at the "Montalcini Global Biotech Tour" in Doha, Qatar, highlighting the Italian biotech ecosystem and the company's initiatives [1][3] Company Developments - Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme patients, indicating potential for reprogramming the tumor microenvironment [6] - The company has initiated a Phase 1/2a study for metastatic Renal Cell Carcinoma, which will explore combinations with immune checkpoint inhibitors [6] - Temferon™ is designed to express immune-therapeutic payloads within the tumor microenvironment, aiming for a durable and targeted response [6] Strategic Partnerships - The event in Doha will feature key stakeholders, including representatives from the Qatar Investment Authority, which manages over $475 billion in assets, indicating potential for cross-border partnerships [4] - CDP Venture Capital, a long-standing investor in Genenta, participated in the company's IPO on Nasdaq in 2021, showcasing ongoing support from institutional investors [3]

Financial Position - As of December 31, 2024, the company had approximately €12.7 million in cash and cash equivalents and marketable securities[628]. - The company incurred a net loss of approximately €8.9 million for the year ended December 31, 2024, with operating activities using approximately €6.2 million of cash[630]. - The company estimates that existing cash and anticipated cash from short-term financing will be sufficient to fund operations into the second quarter of 2026[642]. - The net cash provided by financing activities for the year ended December 31, 2024, was approximately €270,885 from ATM offerings[629]. - A hypothetical 10% movement in USD to EUR exchange rate would impact the net result by approximately €0.5 million for the year ended December 31, 2024[625]. Revenue Generation - The company has not generated any revenue to date and does not expect to do so in the near term[641]. Investment Activities - Investing activities for the year ended December 31, 2024, used approximately €16.4 million to purchase marketable securities, while proceeds from divestment amounted to approximately €23.2 million[634]. - The company plans to use available cash and marketable securities for potential in-licensing, acquisitions, or investments in additional businesses and technologies[646]. Compensation and Governance - The total compensation paid to all directors and senior management for the year ended December 31, 2024, was approximately €1.3 million[671]. - The total cost to the company for all directors and senior managers for the year ended December 31, 2024, was approximately €2.2 million[673]. - The aggregate compensation received by the Board of Statutory Auditors during 2024 was approximately €44,000[677]. - The company established a Compensation, Nomination and Governance Committee to oversee cash compensation and equity award recommendations for executive officers[681]. - The total salary, bonuses, and related benefits for all directors and senior management amounted to €1,258,468[672]. - The company’s cost for each employee is higher than what is actually paid out due to tax and contribution charges affecting labor costs[674]. Corporate Governance - The company follows the historical Italian corporate governance system with separate boards for directors and statutory auditors[675]. - The company has no arrangements with major shareholders or others regarding the selection of directors or senior management[669]. - The company relies on an exemption from the Rule 10A-3 requirements for foreign private issuers with a board of statutory auditors established in accordance with local law[680]. - The company has opted out of shareholder approval requirements for certain share issuances, differing from Nasdaq Listing Rule 5635[686]. - The company follows a traditional model of corporate governance for Italian companies, exempting it from the audit committee requirements established by Rule 10A-3[686]. - The company is not required to have a majority of independent directors on its board, as per Italian law[684]. - Quorum requirements for general meetings of shareholders are governed by the Italian Civil Code, differing from Nasdaq Listing Rule 5620(c)[684]. Employee Relations - As of March 26, 2025, the company had 13 full-time employees, with 11 located in Milan, Italy, and 2 in the U.S.[687]. - The company considers its relationship with employees to be good[687]. - The company relies on consultants and collaborators at SR-TIGET and OSR for various activities including clinical, research and development, and product development[687]. Audit and Reporting - The board of statutory auditors is responsible for the appointment, retention, and oversight of the work of any registered public accounting firm engaged for audit services[686]. - The management report and annual financial statements must be communicated to the auditor and board of statutory auditors at least 30 days prior to the shareholders' meeting[683].

Core Viewpoint - Genenta Science has secured €20 million ($21.9 million) in financing through a Mandatory Convertible Bond from ENEA Tech and Biomedical (ETB) to advance its pipeline, particularly focusing on Temferon for metastatic Renal Cell Cancer (mRCC) [1][2] Financing Details - The total bond amount is €20 million ($21.9 million), with a maturity of three years and mandatory conversion set for March 2028 [6] - The funding structure includes a first tranche of €7.5 million ($8.2 million) for assessing safety in the ongoing Phase 1/2a trial for mRCC, and a second tranche of €12.5 million ($13.7 million) conditional upon achieving safety and tolerability [6] - ETB's equity in Genenta will be capped at 29%, with a maximum conversion price of $17.64 per share [6] Clinical Developments - The Phase 1/2a trial for mRCC has begun enrolling patients, enhancing Genenta's clinical pipeline for Temferon [3] - Recent data from the Phase 1/2a Glioblastoma Multiforme (GBM) trial indicates a two-year survival rate increase to 29% from 25%, with median overall survival now at 17 months [2][3] - Historical data shows that standard care for uMGMT patients has a two-year survival rate of approximately 14% and median overall survival of 13-15 months [2] Strategic Partnerships - ETB conducted extensive due diligence before the investment, indicating confidence in Genenta's long-term value [2] - The partnership with ETB is expected to provide financial stability necessary for advancing the validation of the Temferon platform and pursuing strategic collaborations [2]

Core Insights - Genenta Science has strengthened its partnership with AGC Biologics by amending their Development and Master Services Agreement, introducing an exclusive GMP suite for the manufacturing of Genenta's cell therapy product [1] - The company is advancing its clinical trials, including a Phase 1/2a trial for metastatic Renal Cell Carcinoma (mRCC) and continuing its study on Glioblastoma Multiforme (GBM), with plans to manufacture 27 autologous drug products in 2025 [2][4] - Genenta's CEO emphasized the commitment to patients and the potential of their product, Temferon, to enhance cancer treatment through reprogramming the tumor microenvironment [3] Company Developments - The exclusive GMP suite at AGC Biologics will ensure compliance with cGMP standards, enhancing production capabilities and efficiency for Genenta's cell therapy products [1] - Genenta's first product candidate, Temferon™, aims to express immune-therapeutic payloads within the tumor microenvironment, potentially breaking immune tolerance and enhancing T-cell responses [4] - The company has completed a Phase 1 trial for newly diagnosed GBM patients and initiated a Phase 1/2a study for mRCC, which may include combinations with immune checkpoint inhibitors [4] Upcoming Engagements - Genenta will participate in the Biotech Showcase 2025 from January 13–15, 2025, in San Francisco to present its technology for treating solid tumors [3] - The CEO will also speak at the "Italy on the Move" event on January 15, 2025, aimed at promoting Italy's life sciences sector and attracting international investments [3]